Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Comparison of Human and Experimental Pulmonary Veno-Occlusive Disease.

Manaud G, Nossent EJ, Lambert M, Ghigna MR, Boët A, Vinhas MC, Ranchoux B, Dumas SJ, Courboulin A, Girerd B, Soubrier F, Bignard J, Claude O, Lecerf F, Hautefort A, Florio M, Sun B, Nadaud S, Verleden SE, Remy S, Anegon I, Bogaard HJ, Mercier O, Fadel E, Simonneau G, Vonk Noordegraaf A, Grünberg K, Humbert M, Montani D, Dorfmüller P, Antigny F, Perros F.

Am J Respir Cell Mol Biol. 2020 Mar 25. doi: 10.1165/rcmb.2019-0015OC. [Epub ahead of print]

PMID:
32209028
2.

Phenotype and outcome of PAH patients carrying a TBX4 mutation.

Thoré P, Girerd B, Jaïs X, Savale L, Ghigna MR, Eyries M, Levy M, Ovaert C, Servettaz A, Guillaumot A, Dauphin C, Chabanne C, Boiffard E, Cottin V, Perros F, Simonneau G, Sitbon O, Soubrier F, Bonnet D, Remy-Jardin M, Chaouat A, Humbert M, Montani D.

Eur Respir J. 2020 Feb 20. pii: 1902340. doi: 10.1183/13993003.02340-2019. [Epub ahead of print]

PMID:
32079640
3.

Familial pulmonary arterial hypertension by KDR heterozygous loss of function.

Eyries M, Montani D, Girerd B, Favrolt N, Riou M, Faivre L, Manaud G, Perros F, Gräf S, Morrell NW, Humbert M, Soubrier F.

Eur Respir J. 2020 Jan 24. pii: 1902165. doi: 10.1183/13993003.02165-2019. [Epub ahead of print]

PMID:
31980491
4.

Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension.

Nickel NP, Yuan K, Dorfmuller P, Provencher S, Lai YC, Bonnet S, Austin ED, Koch CD, Morris A, Perros F, Montani D, Zamanian RT, de Jesus Perez VA.

Am J Respir Crit Care Med. 2020 Jan 15;201(2):148-157. doi: 10.1164/rccm.201903-0656CI.

PMID:
31513751
5.

BET Bromodomain Inhibitors and Pulmonary Arterial Hypertension: Take Care of the Heart.

Piquereau J, Perros F.

Am J Respir Crit Care Med. 2019 Nov 1;200(9):1187-1188. doi: 10.1164/rccm.201905-0993LE. No abstract available.

6.

Response by Mendes-Ferreira et al to Letter Regarding Article, "Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension".

Mendes-Ferreira P, Manaud G, Perros F.

Circulation. 2019 Aug 13;140(7):e288-e289. doi: 10.1161/CIRCULATIONAHA.119.041480. Epub 2019 Aug 12. No abstract available.

PMID:
31403844
7.

Characterization of Kcnk3-Mutated Rat, a Novel Model of Pulmonary Hypertension.

Lambert M, Capuano V, Boet A, Tesson L, Bertero T, Nakhleh MK, Remy S, Anegon I, Pechoux C, Hautefort A, Rucker-Martin C, Manoury B, Domergue V, Mercier O, Girerd B, Montani D, Perros F, Humbert M, Antigny F.

Circ Res. 2019 Sep 13;125(7):678-695. doi: 10.1161/CIRCRESAHA.119.314793. Epub 2019 Jul 26.

PMID:
31347976
8.

Smooth Muscle Phenotype in Idiopathic Pulmonary Hypertension: Hyper-Proliferative but not Cancerous.

Perros F, Sentenac P, Boulate D, Manaud G, Kotsimbos T, Lecerf F, Lamrani L, Fadel E, Mercier O, Londono-Vallejo A, Humbert M, Eddahibi S.

Int J Mol Sci. 2019 Jul 22;20(14). pii: E3575. doi: 10.3390/ijms20143575.

9.

The BET Bromodomain Inhibitor I-BET-151 Induces Structural and Functional Alterations of the Heart Mitochondria in Healthy Male Mice and Rats.

Piquereau J, Boet A, Péchoux C, Antigny F, Lambert M, Gressette M, Ranchoux B, Gambaryan N, Domergue V, Mumby S, Montani D, Adcock IM, Humbert M, Garnier A, Rucker-Martin C, Perros F.

Int J Mol Sci. 2019 Mar 27;20(7). pii: E1527. doi: 10.3390/ijms20071527.

10.

Understanding the Similarities and Differences between Hepatic and Pulmonary Veno-Occlusive Disease.

Günther S, Perros F, Rautou PE, Girerd B, Ghigna MR, Cazals-Hatem D, Lau EM, Dorfmüller P, Sitbon O, Valla DC, Humbert M, Montani D.

Am J Pathol. 2019 Jun;189(6):1159-1175. doi: 10.1016/j.ajpath.2019.02.007. Epub 2019 Mar 26. Review.

PMID:
30926335
11.

Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension.

Hautefort A, Mendes-Ferreira P, Sabourin J, Manaud G, Bertero T, Rucker-Martin C, Riou M, Adão R, Manoury B, Lambert M, Boet A, Lecerf F, Domergue V, Brás-Silva C, Gomez AM, Montani D, Girerd B, Humbert M, Antigny F, Perros F.

Circulation. 2019 Feb 12;139(7):932-948. doi: 10.1161/CIRCULATIONAHA.118.033744.

PMID:
30586714
12.

Pulmonary hypertension associated with neurofibromatosis type 1.

Jutant EM, Girerd B, Jaïs X, Savale L, O'Connell C, Perros F, Sitbon O, Humbert M, Montani D.

Eur Respir Rev. 2018 Aug 29;27(149). pii: 180053. doi: 10.1183/16000617.0053-2018. Print 2018 Sep 30. Review.

13.

Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension.

Chaumais MC, O'Connell C, Savale L, Guignabert C, Perros F, Jaïs X, Sitbon O, Humbert M, Montani D.

Int J Clin Pharm. 2018 Aug;40(4):790-794. doi: 10.1007/s11096-018-0712-y. Epub 2018 Aug 13.

PMID:
30101375
14.

Ca2+ handling remodeling and STIM1L/Orai1/TRPC1/TRPC4 upregulation in monocrotaline-induced right ventricular hypertrophy.

Sabourin J, Boet A, Rucker-Martin C, Lambert M, Gomez AM, Benitah JP, Perros F, Humbert M, Antigny F.

J Mol Cell Cardiol. 2018 May;118:208-224. doi: 10.1016/j.yjmcc.2018.04.003. Epub 2018 Apr 7.

PMID:
29634917
15.

The integrated stress response system in cardiovascular disease.

Santos-Ribeiro D, Godinas L, Pilette C, Perros F.

Drug Discov Today. 2018 Apr;23(4):920-929. doi: 10.1016/j.drudis.2018.02.008. Epub 2018 Feb 27. Review.

16.

NMDA-Type Glutamate Receptor Activation Promotes Vascular Remodeling and Pulmonary Arterial Hypertension.

Dumas SJ, Bru-Mercier G, Courboulin A, Quatredeniers M, Rücker-Martin C, Antigny F, Nakhleh MK, Ranchoux B, Gouadon E, Vinhas MC, Vocelle M, Raymond N, Dorfmüller P, Fadel E, Perros F, Humbert M, Cohen-Kaminsky S.

Circulation. 2018 May 29;137(22):2371-2389. doi: 10.1161/CIRCULATIONAHA.117.029930. Epub 2018 Feb 14.

PMID:
29444988
17.

Respiratory effects of trichloroethylene.

Dumas O, Despreaux T, Perros F, Lau E, Andujar P, Humbert M, Montani D, Descatha A.

Respir Med. 2018 Jan;134:47-53. doi: 10.1016/j.rmed.2017.11.021. Epub 2017 Dec 1. Review.

18.

Sirtuin 1 regulates pulmonary artery smooth muscle cell proliferation: role in pulmonary arterial hypertension.

Zurlo G, Piquereau J, Moulin M, Pires Da Silva J, Gressette M, Ranchoux B, Garnier A, Ventura-Clapier R, Fadel E, Humbert M, Lemaire C, Perros F, Veksler V.

J Hypertens. 2018 May;36(5):1164-1177. doi: 10.1097/HJH.0000000000001676.

PMID:
29369849
19.

Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension.

Lambert M, Boet A, Rucker-Martin C, Mendes-Ferreira P, Capuano V, Hatem S, Adão R, Brás-Silva C, Hautefort A, Michel JB, Dorfmuller P, Fadel E, Kotsimbos T, Price L, Jourdon P, Montani D, Humbert M, Perros F, Antigny F.

Cardiovasc Res. 2018 May 1;114(6):880-893. doi: 10.1093/cvr/cvy016.

PMID:
29360952
20.

Identity crisis in pulmonary arterial hypertension.

Ruffenach G, Bonnet S, Rousseaux S, Khochbin S, Provencher S, Perros F.

Pulm Circ. 2018 Jan-Mar;8(1):2045893217746054. doi: 10.1177/2045893217746054.

21.

Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease.

Nossent EJ, Antigny F, Montani D, Bogaard HJ, Ghigna MR, Lambert M, Thomas de Montpréville V, Girerd B, Jaïs X, Savale L, Mercier O, Fadel E, Soubrier F, Sitbon O, Simonneau G, Vonk Noordegraaf A, Humbert M, Perros F, Dorfmüller P.

J Heart Lung Transplant. 2018 May;37(5):647-655. doi: 10.1016/j.healun.2017.09.022. Epub 2017 Oct 4.

PMID:
29108819
22.

Pulmonary endothelial cell DNA methylation signature in pulmonary arterial hypertension.

Hautefort A, Chesné J, Preussner J, Pullamsetti SS, Tost J, Looso M, Antigny F, Girerd B, Riou M, Eddahibi S, Deleuze JF, Seeger W, Fadel E, Simonneau G, Montani D, Humbert M, Perros F.

Oncotarget. 2017 May 19;8(32):52995-53016. doi: 10.18632/oncotarget.18031. eCollection 2017 Aug 8.

23.

Early Development of Right Ventricular Ischemic Lesions in a Novel Large Animal Model of Acute Right Heart Failure in Chronic Thromboembolic Pulmonary Hypertension.

Boulate D, Arthur Ataam J, Connolly AJ, Giraldeau G, Amsallem M, Decante B, Lamrani L, Fadel E, Dorfmuller P, Perros F, Haddad F, Mercier O.

J Card Fail. 2017 Dec;23(12):876-886. doi: 10.1016/j.cardfail.2017.08.447. Epub 2017 Aug 8.

PMID:
28801076
24.

Rescuing BMPR2-driven endothelial dysfunction in PAH: a novel treatment strategy for the future?

Quarck R, Perros F.

Stem Cell Investig. 2017 Jun 14;4:56. doi: 10.21037/sci.2017.05.11. eCollection 2017. No abstract available.

25.

T-type Ca2+ channels elicit pro-proliferative and anti-apoptotic responses through impaired PP2A/Akt1 signaling in PASMCs from patients with pulmonary arterial hypertension.

Sankhe S, Manousakidi S, Antigny F, Arthur Ataam J, Bentebbal S, Ruchon Y, Lecerf F, Sabourin J, Price L, Fadel E, Dorfmüller P, Eddahibi S, Humbert M, Perros F, Capuano V.

Biochim Biophys Acta Mol Cell Res. 2017 Oct;1864(10):1631-1641. doi: 10.1016/j.bbamcr.2017.06.018. Epub 2017 Jun 24.

26.

Use of β-Blockers in Pulmonary Hypertension.

Perros F, de Man FS, Bogaard HJ, Antigny F, Simonneau G, Bonnet S, Provencher S, Galiè N, Humbert M.

Circ Heart Fail. 2017 Apr;10(4). pii: e003703. doi: 10.1161/CIRCHEARTFAILURE.116.003703. Review.

PMID:
28364092
27.

Corrigendum to "A Simple Method to Assess In Vivo Proliferation in Lung Vasculature with EdU: The Case of MMC-Induced PVOD in Rat".

Antigny F, Ranchoux B, Nadeau V, Lau E, Bonnet S, Perros F.

Anal Cell Pathol (Amst). 2017;2017:4697379. doi: 10.1155/2017/4697379. Epub 2017 Feb 6.

28.

Gut-Lung Connection in Pulmonary Arterial Hypertension.

Ranchoux B, Bigorgne A, Hautefort A, Girerd B, Sitbon O, Montani D, Humbert M, Tcherakian C, Perros F.

Am J Respir Cell Mol Biol. 2017 Mar;56(3):402-405. doi: 10.1165/rcmb.2015-0404LE. No abstract available.

PMID:
28248132
30.

Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules.

Nakhleh MK, Amal H, Jeries R, Broza YY, Aboud M, Gharra A, Ivgi H, Khatib S, Badarneh S, Har-Shai L, Glass-Marmor L, Lejbkowicz I, Miller A, Badarny S, Winer R, Finberg J, Cohen-Kaminsky S, Perros F, Montani D, Girerd B, Garcia G, Simonneau G, Nakhoul F, Baram S, Salim R, Hakim M, Gruber M, Ronen O, Marshak T, Doweck I, Nativ O, Bahouth Z, Shi DY, Zhang W, Hua QL, Pan YY, Tao L, Liu H, Karban A, Koifman E, Rainis T, Skapars R, Sivins A, Ancans G, Liepniece-Karele I, Kikuste I, Lasina I, Tolmanis I, Johnson D, Millstone SZ, Fulton J, Wells JW, Wilf LH, Humbert M, Leja M, Peled N, Haick H.

ACS Nano. 2017 Jan 24;11(1):112-125. doi: 10.1021/acsnano.6b04930. Epub 2016 Dec 21.

31.

BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators.

Vengethasamy L, Hautefort A, Tielemans B, Belge C, Perros F, Verleden S, Fadel E, Van Raemdonck D, Delcroix M, Quarck R.

Pflugers Arch. 2016 Nov;468(11-12):1969-1983. Epub 2016 Nov 6.

PMID:
27816994
32.

Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension.

Bonnet S, Provencher S, Guignabert C, Perros F, Boucherat O, Schermuly RT, Hassoun PM, Rabinovitch M, Nicolls MR, Humbert M.

Am J Respir Crit Care Med. 2017 Mar 1;195(5):583-595. doi: 10.1164/rccm.201607-1515PP. Review. No abstract available.

33.

Bromodomain and extra-terminal protein mimic JQ1 decreases inflammation in human vascular endothelial cells: Implications for pulmonary arterial hypertension.

Mumby S, Gambaryan N, Meng C, Perros F, Humbert M, Wort SJ, Adcock IM.

Respirology. 2017 Jan;22(1):157-164. doi: 10.1111/resp.12872. Epub 2016 Aug 18.

34.

Proteomic analysis of vascular smooth muscle cells in physiological condition and in pulmonary arterial hypertension: Toward contractile versus synthetic phenotypes.

Régent A, Ly KH, Lofek S, Clary G, Tamby M, Tamas N, Federici C, Broussard C, Chafey P, Liaudet-Coopman E, Humbert M, Perros F, Mouthon L.

Proteomics. 2016 Oct;16(20):2637-2649. doi: 10.1002/pmic.201500006. Epub 2016 Sep 12.

PMID:
27458111
35.

Role for Runt-related Transcription Factor 2 in Proliferative and Calcified Vascular Lesions in Pulmonary Arterial Hypertension.

Ruffenach G, Chabot S, Tanguay VF, Courboulin A, Boucherat O, Potus F, Meloche J, Pflieger A, Breuils-Bonnet S, Nadeau V, Paradis R, Tremblay E, Girerd B, Hautefort A, Montani D, Fadel E, Dorfmuller P, Humbert M, Perros F, Paulin R, Provencher S, Bonnet S.

Am J Respir Crit Care Med. 2016 Nov 15;194(10):1273-1285.

PMID:
27149112
36.

Endothelial-to-Mesenchymal Transition: An Evolving Paradigm and a Promising Therapeutic Target in PAH.

Stenmark KR, Frid M, Perros F.

Circulation. 2016 May 3;133(18):1734-7. doi: 10.1161/CIRCULATIONAHA.116.022479. Epub 2016 Apr 4. No abstract available.

37.

Response to Letter Regarding Article, "Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Model".

Perros F, Günther S, Ranchoux B, Godinas L, Antigny F, Chaumais MC, Dorfmüller P, Hautefort A, Raymond N, Savale L, Jaïs X, Girerd B, Cottin V, Sitbon O, Simonneau G, Humbert M, Montani D.

Circulation. 2016 Apr 5;133(14):e592-3. doi: 10.1161/CIRCULATIONAHA.116.020946. No abstract available. Erratum in: Circulation. 2016 May 10;133(19):e657-8.

PMID:
27045136
38.

Pulmonary veno-occlusive disease.

Montani D, Lau EM, Dorfmüller P, Girerd B, Jaïs X, Savale L, Perros F, Nossent E, Garcia G, Parent F, Fadel E, Soubrier F, Sitbon O, Simonneau G, Humbert M.

Eur Respir J. 2016 May;47(5):1518-34. doi: 10.1183/13993003.00026-2016. Epub 2016 Mar 23. Review.

39.

Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension.

Antigny F, Hautefort A, Meloche J, Belacel-Ouari M, Manoury B, Rucker-Martin C, Péchoux C, Potus F, Nadeau V, Tremblay E, Ruffenach G, Bourgeois A, Dorfmüller P, Breuils-Bonnet S, Fadel E, Ranchoux B, Jourdon P, Girerd B, Montani D, Provencher S, Bonnet S, Simonneau G, Humbert M, Perros F.

Circulation. 2016 Apr 5;133(14):1371-85. doi: 10.1161/CIRCULATIONAHA.115.020951. Epub 2016 Feb 24.

PMID:
26912814
40.

β-blockers in pulmonary arterial hypertension: generation might matter.

Malenfant S, Perros F.

Eur Respir J. 2016 Feb;47(2):682-4. doi: 10.1183/13993003.01244-2015. No abstract available.

41.

MicroRNA networks in pulmonary arterial hypertension: share mechanisms with cancer?

Courboulin A, Ranchoux B, Cohen-Kaminsky S, Perros F, Bonnet S.

Curr Opin Oncol. 2016 Jan;28(1):72-82. doi: 10.1097/CCO.0000000000000253. Review.

PMID:
26569423
42.

Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease.

Montani D, Lau EM, Descatha A, Jaïs X, Savale L, Andujar P, Bensefa-Colas L, Girerd B, Zendah I, Le Pavec J, Seferian A, Perros F, Dorfmüller P, Fadel E, Soubrier F, Sitbon O, Simonneau G, Humbert M.

Eur Respir J. 2015 Dec;46(6):1721-31. doi: 10.1183/13993003.00814-2015. Epub 2015 Nov 5.

43.

Response.

Hautefort A, Girerd B, Montani D, Cohen-Kaminsky S, Price L, Lambrecht BN, Humbert M, Perros F.

Chest. 2015 Oct;148(4):e132-e133. doi: 10.1378/chest.15-1573. No abstract available.

PMID:
26437827
44.

Bone morphogenetic protein receptor type II and inflammation are bringing old concepts into the new pulmonary arterial hypertension world.

Perros F, Bonnet S.

Am J Respir Crit Care Med. 2015 Oct 1;192(7):777-9. doi: 10.1164/rccm.201506-1115ED. No abstract available.

PMID:
26426782
45.

Dexamethasone induces apoptosis in pulmonary arterial smooth muscle cells.

Price LC, Shao D, Meng C, Perros F, Garfield BE, Zhu J, Montani D, Dorfmuller P, Humbert M, Adcock IM, Wort SJ.

Respir Res. 2015 Sep 18;16:114. doi: 10.1186/s12931-015-0262-y.

46.

Potassium channels in pulmonary arterial hypertension.

Boucherat O, Chabot S, Antigny F, Perros F, Provencher S, Bonnet S.

Eur Respir J. 2015 Oct;46(4):1167-77. doi: 10.1183/13993003.00798-2015. Epub 2015 Sep 4. Review.

47.

Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models.

Perros F, Günther S, Ranchoux B, Godinas L, Antigny F, Chaumais MC, Dorfmüller P, Hautefort A, Raymond N, Savale L, Jaïs X, Girerd B, Cottin V, Sitbon O, Simonneau G, Humbert M, Montani D.

Circulation. 2015 Sep 1;132(9):834-47. doi: 10.1161/CIRCULATIONAHA.115.014207. Epub 2015 Jun 30.

PMID:
26130118
48.

miR-223 reverses experimental pulmonary arterial hypertension.

Meloche J, Le Guen M, Potus F, Vinck J, Ranchoux B, Johnson I, Antigny F, Tremblay E, Breuils-Bonnet S, Perros F, Provencher S, Bonnet S.

Am J Physiol Cell Physiol. 2015 Sep 15;309(6):C363-72. doi: 10.1152/ajpcell.00149.2015. Epub 2015 Jun 17.

49.

Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension.

Perros F, Ranchoux B, Izikki M, Bentebbal S, Happé C, Antigny F, Jourdon P, Dorfmüller P, Lecerf F, Fadel E, Simonneau G, Humbert M, Bogaard HJ, Eddahibi S.

J Am Coll Cardiol. 2015 Feb 24;65(7):668-80. doi: 10.1016/j.jacc.2014.11.050.

50.

Endothelial-to-mesenchymal transition in pulmonary hypertension.

Ranchoux B, Antigny F, Rucker-Martin C, Hautefort A, Péchoux C, Bogaard HJ, Dorfmüller P, Remy S, Lecerf F, Planté S, Chat S, Fadel E, Houssaini A, Anegon I, Adnot S, Simonneau G, Humbert M, Cohen-Kaminsky S, Perros F.

Circulation. 2015 Mar 17;131(11):1006-18. doi: 10.1161/CIRCULATIONAHA.114.008750. Epub 2015 Jan 15.

PMID:
25593290

Supplemental Content

Loading ...
Support Center